RAPT Therapeutics: Dip Following FDA Clinical Hold Creates Asymmetric Opportunity

Shidlovski/iStock via Getty Images Thesis overview RAPT Therapeutics (NASDAQ:RAPT) is developing oral small molecule therapies for inflammation (atopic dermatitis and asthma) and oncology indications. The most advanced candidate is zelnecirnon (ZEL) currently in ph2 stage for the indications of atopic dermatitis (AD) and asthma, with promising phase 1 safety and efficacy results in AD. RAPT was trading at a market cap close to $900M up until recently, when RAPT announced an FDA clinical hold due to hepatic ...